Medtronic presents results from study of PulseSelect PFA System

Medtronic announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect Pulsed Field Ablation System in treating atrial fibrillation. Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins and 96% of patients had all veins isolated. Results were presented as a late breaking clinical trial at the Asia Pacific Heart Rhythm Society meeting in Sydney, Australia. “Real-world evidence on chronic lesion formation and durability is critical as use of PFA for the treatment of Afib rapidly increases, making these results impactful and timely for the electrophysiology community,” said Devi Nair, M.D., FHRS, Director of Cardiac Electrophysiology & Research, St. Bernard’s Medical Center & Arrhythmia Research Group, Jonesboro, Arkansas. “Our research shows that treatment with PulseSelect results in durable lesion formation, which is the cornerstone of successful pulmonary vein isolation and an important addition to previous evidence establishing the safety and effectiveness of this technology.”